I-Mab initiated with a Buy at BTIG

 BTIG initiated coverage of I-Mab (IMAB) with a Buy rating and $7 price target The firm believes givastomig has “best-in-class potential” to redefine first-line gastric cancer treatment. Unlike Zolbetuximab, givastomig’s 10-times more potent conditional 4-1BB design drives activity across CLDN18.2-low and PD-L1-low populations, which doubles the addressable market, the analyst tells investors in a research note. BTIG believes the drug’s early durability and “clean” safety profile validate its “differentiated mechanism.” It sees a near-term catalyst for I-Mab shares with a Q1 of 2026 data release.

https://www.msn.com/en-us/money/savingandinvesting/i-mab-initiated-with-a-buy-at-btig/ar-AA1MbQdu